Skip to content

Addiction research published in 2024

Page 2 of 6: studies 21 to 40 of 114, newest first. Back to the addiction overview

Studies

Psilocybin administered following extinction sessions does not affect subsequent cocaine cue reinstatement in male and female rats and mice.

Neuroscience November 1, 2024 Veronika Pohořalá, Martin Kuchař, Rainer Spanagel et al. 3 citations

There are currently no pharmacological treatments for cocaine use disorder. Recently there has been a great deal of interest in the potential of psychedelic drugs such as psilocybin to treat psychiatric disorders. Human studies have indicated that a single administration of psilocybin can have long-lasting effects. Few preclinical studies have examined a role for psilocybin in addiction models....

DOI: 10.1016/j.neuroscience.2024.09.006 (opens in new tab) Full text (opens in new tab) Psilocybin Addiction treatment Psychedelic research Substance abuse +6

5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA.

bioRxiv : the preprint server for biology October 22, 2024 Matthew B Pomrenze, Sam Vaillancourt, Juliana S Salgado et al. 1 citation preprint

MDMA is a promising adjunct to psychotherapy and has well-known abuse liability, although less than other amphetamine analogs. While the reinforcing dopamine (DA)-releasing properties of MDMA are on par with methamphetamine (METH), MDMA is a far more potent serotonin (5-HT) releaser, via the 5-HT transporter (SERT). MDMA-mediated 5-HT release in a major reward center, the nucleus accumbens...

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Journal of Affective Disorders October 15, 2024 Angela T H Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur et al. 13 citations

Ketamine and esketamine are increasingly prescribed in the treatment of resistant mood disorders and persons at risk of suicide. Ketamine is a drug of misuse with increasing non-therapeutic use in the general population. Herein, our aim was to determine whether ketamine and/or esketamine are disproportionately associated with reports of substance and/or alcohol misuse. Replicating a similar...

Mental Health Facilities With Ketamine Infusion Therapy in the United States in 2020: Co-Location of Dual Diagnosis Mental Health and Substance Use Disorder Treatment

Carolina Digital Repository October 9, 2024 Orrin D. Ware

Ketamine is an anesthetic that has been identified as an effective therapy for depressive disorders and related symptoms. Some studies have identified ketamine as having the potential to reduce substance use among individuals with a substance use disorder (SUD)-alongside psychotherapy. Further, SUDs often co-occur with depressive disorders. Using the National Mental Health Services Survey 2020,...

DOI: 10.17615/rd8y-nq91 (opens in new tab) Ketamine Mental health Dual diagnosis Dual grammatical number +1

The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists

American Journal of Psychiatry October 9, 2024 Caesar G. Imperio, Frances R. Levin, Diana Martínez 9 citations

Substance use disorder (SUD) is common in psychiatric patients and has a negative impact on health and well-being. However, SUD often goes untreated, and there is a need for psychiatrists, of all specialties, to address this pervasive clinical problem. In this review, the authors' goal is to provide a resource that describes treatments for SUD, using neuroscience as a framework. They discuss...

Navigating Buprenorphine Therapy: A Closer Look at Microdosing vs. Macrodosing for Pain Management and Opioid Addiction - A Narrative Review.

Addiction and Health October 1, 2024 Zachary I Merhavy, Marcos Flores, Eliu Rivera et al.

Buprenorphine therapy has emerged as a primary therapy method for both opioid addiction and chronic pain; however, the «one size fits all» approach to buprenorphine administration is no longer tenable. This review analyzes the pharmacology of both dosing approaches and their clinical outcomes, safety profiles, and societal implications, providing valuable insights for healthcare professionals....

DOI: 10.34172/ahj.1590 (opens in new tab) Full text (opens in new tab) Microdosing Buprenorphine therapy Macrodosing Opioid addiction +1

Mindfulness as a Path to Freedom from Internet Addiction in Adolescents: A Narrative Review.

Cureus October 1, 2024 Priyadarsini Samanta, Ipsa Mohapatra, Rituparna Mitra et al. 6 citations

In recent years, Internet Addiction Disorder (IAD) has become a major mental health concern among adolescents, with detrimental effects on social relationships, academic performance, and emotional well-being. The focus of mindfulness-based interventions (MBIs) on improving self-awareness, emotional regulation, and cognitive flexibility has drawn interest in MBIs as possible therapeutic...

DOI: 10.7759/cureus.72544 (opens in new tab) Full text (opens in new tab) Mindfulness Adolescents Emotional regulation Executive functioning +3

Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand.

Australian & New Zealand Journal of Psychiatry October 1, 2024 Alistair Carroll, Adam Bayes, Mark Montebello et al. 10 citations

Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict...

DOI: 10.1177/00048674241242315 (opens in new tab) Full text (opens in new tab) Drug dependence Regulations Ketamine therapy Mental health treatment +3

Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial.

Contemporary Clinical Trials Communications October 1, 2024 Erica Eaton, Christy Capone, Brian J Gully et al. 2 citations

Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) commonly co-occur and are associated with more severe symptomatology than either disorder alone, increased risk of suicide, and poorer response to existing treatments. A promising therapeutic intervention is the integration of 3,4-methylenedioxymethamphetamine (MDMA) and psychotherapy. The Food and Drug Administration (FDA)...

Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.

CNS Drugs October 1, 2024 Anton Gomez-Escolar, Daniel Folch-Sanchez, Joanna Stefaniuk et al. 16 citations

Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are currently being explored for the treatment of SUDs, yet with less empirical clinical evidence than for other mental health disorders, such as depression or post-traumatic stress disorder (PTSD). In this...

DOI: 10.1007/s40263-024-01101-3 (opens in new tab) Full text (opens in new tab) Addiction treatment Clinical research Psychedelics Mental health therapy +1

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction

European Addiction Research September 25, 2024 Ioanna A. Vamvakopoulou, David Nutt 13 citations

Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-20th century, we have seen the re-emergence of psychedelics in a therapeutic setting and more specifically for the treatment of addiction. This article aims to review research over the past 40 years using classic (psilocybin, lysergic acid...

Disrupting Substance Use Disorder: The Chemistry of Iboga Alkaloids.

European journal of organic chemistry September 23, 2024 Alexander J Hughes, Charles R Hamelink, Steven D Townsend 5 citations

The iboga alkaloids are a family of monoterpene indole alkaloids first discovered from the root of Tabernanthe iboga. The major alkaloid constituent in the root, ibogaine, has garnered interest for its anti-addictive properties. Ibogaine has been shown to reduce opiate, amphetamine, alcohol, and nicotine self-administration in rodents. However, ibogaine itself is less than optimal as a...

Ketamine Therapy in Patients of Alcohol Use Disorder: A Prospective Pilot Study to Evaluate Abstinence Rate with This Add-on Treatment Modality

Annals of Indian Psychiatry September 3, 2024 Nidhi Purushottum Marvania, Anto Leroy Rayan, Dhruti Vijaykumar Merchant et al. 3 citations

Background: Alcohol use disorders (AUDs) are emerging as a substance use disorder having various psychological and physical ill effects leading to hampering of individual’s productivity and functioning. Aims: The aim of this study was to evaluate the efficacy of ketamine in enhancing confidence levels to abstain from alcohol. Methods: Eighteen patients were administered ketamine intravenously...

Self-transcendence through the lens of ontological addiction: correlates of prosociality, competitiveness and pro-nature behavior

Current Psychology September 1, 2024 Paul Barrows, William van Gordon, Miles Richardson

AbstractSelf-transcendence and the associated decrease in ego-centeredness are understood to foster altruistic and positive behaviors that promote prosociality and pro-environmental actions. However, the lack of an agreed valid and reliable measure of self-transcendence has posed difficulties in examining this subject. The main aim of this study was to use the recently developed Ontological...

A preliminary investigation of the acute effects of delta-9-tetrahydrocannabinol on pain and opioid attentional bias among persons with opioid use disorder.

Journal of Psychiatric Research September 1, 2024 Noah R Wolkowicz, Mehmet Sofuoglu, Brian Pittman et al.

Attentional bias (AB) is believed to be an important factor in the development and maintenance of both opioid use disorder (OUD) and chronic pain. Cannabis and its main psychoactive constituent, delta-9-tetrahydrocannabinol (THC), produce analgesic effects via processes that are potentially relevant to AB and is commonly used by persons with OUD. This exploratory study investigated if THC...

Intellectual Property of Psychedelics for Addiction Treatment: Enabling Access and Protecting Innovation Opportunities Through Preserving the Public Domain.

Journal of Studies on Alcohol and Drugs September 1, 2024 Sisi Li, Taylor Kurtzweil, Shahin Shams et al. 3 citations

Recent research has shown potential for psychedelic therapeutics as addiction treatments; however, some academic institutions, commercial entities, and individuals are attempting to monopolize psychedelic compounds through exploiting the patent process. This Perspective article describes efforts that have been devised to mitigate exclusionary patent practices pertinent to psychedelic...

Exploring ketamine's reinforcement, cue-induced reinstatement, and nucleus accumbens cFos activation in male and female long evans rats.

Neuropharmacology September 1, 2024 Devin P Hagarty, Adam Dawoud, Alfonso Brea Guerrero et al. 6 citations

Ketamine (KET), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, has rapid onset of antidepressant effects in Treatment-Resistant Depression patients and repeated infusions are required to sustain its antidepressant properties. However, KET is an addictive drug, and so more preclinical and clinical research is needed to assess the safety of recurring treatments in both sexes....

DOI: 10.1016/j.neuropharm.2024.110008 (opens in new tab) Full text (opens in new tab) Dose-response Sex differences Cfos Addiction-risk +3

Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.

Expert Opinion on Emerging Drugs September 1, 2024 Sophie Köhne, Thomas Hillemacher, Alexander Glahn et al. 16 citations

Alcohol Use Disorder (AUD) poses an ongoing significant global health burden. AUD is highly prevalent and affects not only the individuals with AUD, but also their communities and society at large. Even though pharmacotherapy is an integral part of AUD treatment, the few available substances show limited efficacy and limited clinical impact. Thus, there is a need for new innovative...

AA, Bill Wilson, Carl Jung and LSD.

Journal of Analytical Psychology September 1, 2024 Robert McDonnell, John Moriarty, Ian Mc Cabe et al. 2 citations

Alcoholics Anonymous (AA) is an established resource for people suffering from alcohol use disorder (AUD). However, Bill Wilson, the co-founder of AA, in his second letter to Jung referred to its low success rate. One evidence-based alternative, dating back to the 1950s, is the clinical use of lysergic acid diethylamide (LSD) for treating AUD. Bill Wilson was a strong advocate of using LSD as a...

Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders.

Journal of Studies on Alcohol and Drugs September 1, 2024 Anja Loizaga-Velder, Armando Loizaga Pazzi 4 citations

This article provides an intercultural transdisciplinary perspective on the Indigenous roots of the resurging field of psychedelic science in the management of substance use disorders (SUDs). Ritual uses of entheogens (i.e., psychedelics of natural origin) are elaborate technologies for navigating, containing, and therapeutically directing non-ordinary states of consciousness induced by these...

DOI: 10.15288/jsad.23-00011 (opens in new tab) Full text (opens in new tab) Addiction-treatment Indigenous-medicine Psychedelic-therapy Traditional-healing +1